A detailed history of Stem Point Capital LP transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Stem Point Capital LP holds 1,481,809 shares of FOLD stock, worth $14.2 Million. This represents 4.74% of its overall portfolio holdings.

Number of Shares
1,481,809
Previous 1,495,047 0.89%
Holding current value
$14.2 Million
Previous $14.8 Billion 6.71%
% of portfolio
4.74%
Previous 4.36%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$9.55 - $12.09 $126,422 - $160,047
-13,238 Reduced 0.89%
1,481,809 $15.8 Billion
Q2 2024

Aug 13, 2024

SELL
$9.04 - $11.75 $470,929 - $612,104
-52,094 Reduced 3.37%
1,495,047 $14.8 Billion
Q1 2024

May 13, 2024

BUY
$11.43 - $14.24 $7.82 Million - $9.74 Million
684,326 Added 79.31%
1,547,141 $18.2 Billion
Q4 2023

Feb 12, 2024

BUY
$9.97 - $14.52 $8.6 Million - $12.5 Million
862,815 New
862,815 $12.2 Billion

Others Institutions Holding FOLD

About AMICUS THERAPEUTICS, INC.


  • Ticker FOLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 280,497,984
  • Market Cap $2.69B
  • Description
  • Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...
More about FOLD
Track This Portfolio

Track Stem Point Capital LP Portfolio

Follow Stem Point Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stem Point Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Stem Point Capital LP with notifications on news.